People taking the experimental drug amycretin were found to lose almost twice as much weight over a 12-week period as the average weight loss seen with semaglutide.
Pharmaceutical company Novo Nordisk isn’t sitting on its laurels when it comes to weight loss. The Danish-based company has just revealed preliminary data suggesting that its experimental drug amycretin can help people lose even more weight than its already blockbuster drug semaglutide, the active ingredient in Ozempic and Wegovy. Even better, amycretin is taken as a pill, as opposed to the injections needed for Ozempic and Wegovy.
For comparison, people taking high dose semaglutide in clinical trials have been found to lose about 6% of their body weight on average after three months and about 15% body weight after six months. That raises the tantalizing possibility that people on amycretin could expect to lose 25% or more weight during the same period, an average level of weight loss not seen with any current obesity medication and comparable with the most effective bariatric surgeries.
“It’s almost like a miracle pill,” Susan Spratt, an endocrinologist and the senior medical director for the Population Health Management Office at Duke Health,Novo Nordisk’s data has yet to be vetted by outside experts, an important part of the scientific process. And it’s still only Phase I data, which is explicitly only designed to tell us whether a drug is safe to keep testing in humans, not to confirm its effectiveness.
The pharmacology behind amycretin does lend support to the idea that it could beat semaglutide. Semaglutide mimics the gut hormone GLP-1, which helps regulate our blood sugar and sense of hunger, among other things. But amycretin is designed to mimic both GLP-1 and another hormone key to our hunger and blood sugar regulation, amylin.
Semaglutide doesn't work for everyone and can have side effects, but a study in mice may point to a solution.9/2/2024, 7:02 am
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Weight-loss pill from Wegovy makers cut body weight by up to 13% in early trialNovo Nordisk, the maker of Ozempic and Wegovy, said its experimental weight-loss pill lowered participants' body weight by up to 13% after three months of its Phase 1 clinical trial.
Read more »
Weight-loss drug safe, effective for kids as young as 6, study saysSaxenda was the FDA's first approved drug to treat obesity in adults back in 2014.
Read more »
Novo Nordisk weight-loss drug is effective for kids as young as 6, study showsA drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6 when combined with diet and exercise, a small new study…
Read more »
Novo Nordisk weight-loss drug is effective for kids as young as 6, study showsA drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6 when combined with diet and exercise, a small new study…
Read more »
Healthy Returns: Eli Lilly gains momentum against Novo Nordisk in the weight loss drug marketEli Lilly may be starting to gain an edge over Novo Nordisk in the GLP-1 market. Meanwhile, Stryker will acquire artificial intelligence startup Care.ai.
Read more »
Healthy Returns: Eli Lilly gains momentum against Novo Nordisk in the weight loss drug marketEli Lilly may be starting to gain an edge over Novo Nordisk in the GLP-1 market. Meanwhile, Stryker will acquire artificial intelligence startup Care.ai.
Read more »